NASDAQ:TCRT Alaunos Therapeutics Q2 2025 Earnings Results & Report $2.60 +0.43 (+19.50%) As of 02:20 PM Eastern This is a fair market value price provided by Massive. Learn more. Alaunos Therapeutics beat analyst earnings expectations in its Q2 2025 results, released August 14, 2025. The company reported EPS of -$0.63 versus the -$5.3340 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2025Report DateAugust 14, 2025TimeBefore Market OpensConference Call7:00 AM ET Alaunos Therapeutics EPS ResultsActual EPS-$0.63Consensus EPS -$5.3340Beat/MissBeat by +$4.7040One Year Ago EPSN/AEPS Beat Rate5 of last 8 quartersAlaunos Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsAlaunos Therapeutics' Q3 2026 earnings is estimated for Tuesday, November 17, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 13, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) Alaunos Therapeutics Q2 2025 Earnings FAQ Did Alaunos Therapeutics beat earnings estimates for Q2 2025? Alaunos Therapeutics (NASDAQ:TCRT) reported earnings of -$0.63 per share for Q2 2025, beating the consensus estimate of -$5.3340. The report was announced on Thursday, August 14, 2025. When is Alaunos Therapeutics' next earnings date? Alaunos Therapeutics' next earnings date is estimated for Tuesday, November 17, 2026. MarketBeat tracks confirmed and estimated earnings dates for Alaunos Therapeutics on the company's earnings history page. Alaunos Therapeutics Earnings HeadlinesBio Pre-Market Movers: TCRT, ICCC, MNDR Chart The CourseOctober 13 at 3:03 PM | rttnews.comAlaunos Therapeutics Announces Acquisition of Velaris TherapeuticsOctober 13 at 3:03 PM | finance.yahoo.comTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of Saudi Arabia's largest oil field, with potential to last two million years. While the One Big Beautiful Bill Act eliminated federal credits for solar, wind, and EVs, this energy source was reclassified alongside oil and nuclear power and given eight years of tax credits. Google signed a 15-year contract, and Bill Gates committed $100 million. One company controls the entire supply chain behind this discovery.October 16 at 1:00 AM | Behind the Markets (Ad)Alaunos Therapeutics Completes Velaris Acquisition; Shares SurgeOctober 13 at 3:03 PM | finance.yahoo.comAlaunos Therapeutics Acquires Velaris Therapeutics, Secures $350 Million Private Placement to Advance Pulmonary Hypertension PipelineOctober 13 at 10:51 AM | quiverquant.comQParagon Labs Expands Leadership Team with Former Apogee Executives; Velaris Therapeutics Acquired by Alaunos Therapeutics, Inc.October 13 at 7:00 AM | prnewswire.comSee More Alaunos Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Alaunos Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Alaunos Therapeutics and other key companies, straight to your email. Email Address About Alaunos TherapeuticsAlaunos Therapeutics (NASDAQ:TCRT) is a biotechnology company focused on developing genetically engineered T-cell therapies for the treatment of cancer, particularly solid tumors. Its research centers on T-cell receptor (TCR) therapies, which are designed to equip a patient’s immune cells to recognize and attack tumor-specific targets. The company’s development programs have included TCR-T candidates directed at cancer-associated antigens such as NY-ESO-1 and LAGE-1a. Alaunos has also worked on a TCR library approach intended to support the development of personalized therapies targeting tumor mutations. These programs have been investigated primarily through early-stage clinical and research activities. Alaunos was formerly known as Ziopharm Oncology, adopting its current name in 2022. Its work has involved collaborations with academic and research institutions, including the National Cancer Institute, and has primarily focused on cancer immunotherapy research in the United States. The company’s publicly reported activities and development programs have evolved over time, and investors should consult its latest filings for current operational and clinical updates.View Alaunos Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Bank of America Stock Sell-Off Looks Like a Buying OpportunityMorgan Stanley Beats on Earnings, But Shares Fall on Trading MixFundamental and Technicals Signals Align for Costco: Is the Stock Finally Breaking Out?Palantir's Potential Next Catalyst After Retail Profit-TakingApple Cut iPhone 18 Orders; What Does It Mean For Suppliers?Domino’s Pizza: As Cheap As It Gets, Nowhere to Go But UpFastenal Flashes Bullish Signal as Uptrend Holds Despite Margin Pressure Upcoming Earnings HDFC Bank (10/17/2026)ICICI Bank (10/17/2026)America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026)GE Aerospace (10/20/2026)3M (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
